echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The price of star drugs fell by more than 90% in the national drug collection and reverse-pushing drug companies.

    The price of star drugs fell by more than 90% in the national drug collection and reverse-pushing drug companies.

    • Last Update: 2020-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This time, there are a lot of star drugs to give the "jump price", so that patients see the real benefits.
    the same time, in the profit space is pressed against the background, domestic pharmaceutical companies are also actively seeking to live.
    the third batch of medicines has been collected! Sugar-lowering drugs fell to less than one cent per tablet Recently, the third batch of centralized procurement of drugs organized by the state organization produced the results of the proposed election.
    reported that a total of 189 enterprises participated in the procurement, resulting in 125 enterprises to be selected, 191 products to be selected, the average price reduction of the products to be selected 53%, the highest reduction of 95%.
    from the point of view of drug types, it is proposed to include 56 varieties, involving more than 300 products, treatment of disease types related to malignant tumors, hypertension, diabetes, mental illness and so on.
    compared with the second batch of national collection, the third batch of procurement rules have also been fine-tuned and optimized, the maximum number of selected enterprises from the original 6, further increased to 8.
    according to the 20th published "National drug centralized procurement of the results of the proposed selection", the collection of a total of 55 varieties of successful procurement, the number of drug varieties close to the first two batches of the total.
    addition to the number of drug varieties far ahead of the first two batches of collection, the proposed low price of the drug also caused concern.
    To diabetes commonly used drug metformin as an example, in this collection, metformin tablets 0.25g product regulations, Chongqing Core Pharmaceutical reported 0.015 yuan / tablet price, the lowest price per tablet, a decline of more than 90%.
    is a real benefit for the vast majority of patients.
    hu Shanlian, a professor at Fudan University's School of Public Health, said in an interview with the media that the third national collection of 55 drugs at a time, in the future to improve the concentration of pharmaceutical enterprises, regulate drug circulation links, establish standards for payment of medical insurance drugs, improve the hospital drug catalog, improve the access of patients to drugs, reduce medical costs played a great role.
    Transnational pharmaceutical enterprises "great retreat" domestic pharmaceutical enterprises into the "price war" in the past, many multinational pharmaceutical companies in the original research drug species in the domestic market dominated, after two batches of collection, the decline in drug prices of foreign-funded enterprises has been highly concerned.
    , however, this collection, multinational pharmaceutical companies have appeared a collective "great retreat" phenomenon, many enterprises have been "out."
    From the publicity results, foreign investment, only the ingredients of methylcobalamin tablets, Ukip's left ethyl laxitan injection with a thick solution, Pfizer's lynazine tablets and other original research drugs winning the bid.
    Taking the sodium chloride injection of moxisa hydrochloric acid as an example, according to wind medicine bank data, the domestic sample hospital sales of sodium chloride injections in Moxiza star in 2019 amounted to 913 million yuan, accounting for about 96.08 percent of Bayer's sales revenue as the original pharmaceutical plant.
    , however, in this collection, the sodium chloride injection of moxisa star hydrochloric acid was won by Tianjin Red Day Pharmaceuticals and Hunan Aicco Pharmaceuticals, and Bayer, the original research drug factory, was out.
    , Tianjin Red Day and Hainan Aike quoted 32.8 yuan and 35.27 yuan, respectively.
    " for the original research brand medicine, if they and domestic prices are actually unable to keep up, because generally will fall to 70%, 80%, even after the number may be more, but there is no profit.
    " China Pharmaceutical Business Association vice president, Baiyang Pharmaceutical Group Chairman Fu Gang in an interview with reporters analysis.
    contrast with foreign pharmaceutical companies, although domestic pharmaceutical companies occupy an absolute advantage, but also entered the "price war."
    this collection, metformin oral normal release agent type (0.25g, 0.5g) over-evaluation enterprises reached 29, metformin slow-release control agent-type (0.5g) over-evaluation of 17 enterprises, the competition is fierce, beyond imagination.
    according to the published results of the proposed selection, only the hydrochloric acid metformin slow release tablets (0.5g) there are Tianfang Pharmaceuticals, Beijing Wanhui Shuanghe Pharmaceuticals, Shi Pharmaceutical Group and other 8 enterprises won the bid.
    , Beijing Wanhui Shuanghe Pharmaceuticals' proposed selection price is only 0.78 yuan, the average price of a single piece is less than 1 dime, the supply provinces cover Inner Mongolia, Heilongjiang, Shanghai, Hunan.
    third round of collection, the pharmaceutical industry is undergoing a shuffle Since December 2018, when the "4 plus 7" pilot cities launched the purchase of drug belt volume, pharmaceutical companies have gone through three rounds of "baptism".
    In January this year, the State Health Insurance Administration and other five departments issued a "notice" clearly, the second batch of state organizations centralized procurement and use of drugs will no longer select some areas to carry out the pilot, by the country's provinces and Xinjiang Production and Construction Corps to form a procurement alliance, all public medical institutions and military medical institutions in the alliance region to participate.
    , the above-mentioned Notice also mentions that medical insurance fixed-point social-run medical institutions, medical insurance fixed-point retail pharmacies can participate voluntarily.
    , the local upgraded version of the volume of procurement has also been published.
    For example, recently, the Shanghai Municipal Health Insurance Bureau and the Shanghai Municipal Health And Safety Commission jointly issued the Opinions, encouraging public medical institutions to carry out centralized bargaining procurement of drugs with volume and budget on the basis of adhering to quality priority, ensuring dosage and guaranteeing repayment, giving priority to drugs not included in the national and municipal procurement, especially price abnormal drugs (such as prices significantly higher than other brands or price increases of the same variety), as well as self-funded medicines.
    In the industry's view, the expansion of drug collection also means that for domestic pharmaceutical companies, competition will become more intense, domestic generic drugs lie to make money "good days" to the end, and seems to come faster than everyone expected.
    , many pharmaceutical companies, whether foreign or domestic, sometimes developed a new drug that could recruit two or three thousand marketing teams, said Mr. Fu.
    is too high a percentage of sales costs.
    it is clear that such a mode of operation can no longer adapt to the new market environment.
    of life and symbica, where is the way out for pharmaceutical companies? There is no doubt that China's pharmaceutical industry is undergoing a transformation, and in the face of industry changes and the possible reshuffle effect, where is the future way out for pharmaceutical companies? Innovation, of course, is the constant law of seeking new advantages.
    , for example, Hengrui Pharmaceuticals, which has won the bid for several drugs, has been increasing its investment in research and development in recent years.
    its 2019 annual report, Hengrui Pharmaceuticals invested 3,896 million yuan in research and development in 2019, up 45.90 percent year-on-year, with research and development investment accounting for 16.73 percent of sales revenue.
    for most of the unelounded companies, in addition to accelerating innovation, the urgent task is to switch to the off-court market.
    , however, how so many branded products continue to release value in the retail market, but also pharmaceutical companies need to crack the dilemma.
    industry environment forced enterprises to reform the marketing model.
    Paygang to Baiyang Pharmaceuticals set up a "commercial platform" for example, "commercial platform" through across the channel management, multi-category coordination and digital marketing, in-depth links to medical institutions, retail enterprises and industrial enterprises, optimize marketing costs, improve marketing efficiency and standardization.
    " out-of-hospital market individual pharmaceutical companies to build their own national sales team costs are too high, and this commercial platform enterprises, like highways, pharmaceutical companies' products like a car, the more cars on the road, the lower the cost.
    " Fu Gang said that pharmaceutical companies fighting each other, relying on several products to support thousands of people or even tens of thousands of people of the national marketing team is no longer realistic, industrial enterprises should treat all downstream customers as a key link in their own value chain, and actively cooperate to seek symbly and win-win situation.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.